GNS Stock Overview
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£26.34|
|52 Week High||UK£63.10|
|52 Week Low||UK£21.86|
|1 Month Change||1.00%|
|3 Month Change||8.04%|
|1 Year Change||-54.39%|
|3 Year Change||1.70%|
|5 Year Change||46.66%|
|Change since IPO||1,851.11%|
Recent News & Updates
A Look At The Intrinsic Value Of Genus plc (LON:GNS)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Genus plc ( LON:GNS...
Is Genus (LON:GNS) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Genus (LON:GNS) Has Re-Affirmed Its Dividend Of UK£0.10
The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend of UK£0.10 per share on the 31st of March...
|GNS||GB Biotechs||GB Market|
Return vs Industry: GNS underperformed the UK Biotechs industry which returned -39.6% over the past year.
Return vs Market: GNS underperformed the UK Market which returned -6.4% over the past year.
|GNS Average Weekly Movement||5.3%|
|Biotechs Industry Average Movement||6.9%|
|Market Average Movement||5.4%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.7%|
Stable Share Price: GNS is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GNS's weekly volatility (5%) has been stable over the past year.
About the Company
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
Genus Fundamentals Summary
|GNS fundamental statistics|
Is GNS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GNS income statement (TTM)|
|Cost of Revenue||UK£342.10m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 08, 2022
|Earnings per share (EPS)||0.57|
|Net Profit Margin||6.49%|
How did GNS perform over the long term?See historical performance and comparison
1.1%Current Dividend Yield
Is GNS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GNS?
Other financial metrics that can be useful for relative valuation.
|What is GNS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does GNS's PE Ratio compare to its peers?
|GNS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
OXB Oxford Biomedica
CIR Circassia Group
Price-To-Earnings vs Peers: GNS is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the peer average (33x).
Price to Earnings Ratio vs Industry
How does GNS's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: GNS is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the UK Biotechs industry average (38.1x)
Price to Earnings Ratio vs Fair Ratio
What is GNS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||46.4x|
|Fair PE Ratio||39x|
Price-To-Earnings vs Fair Ratio: GNS is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the estimated Fair Price-To-Earnings Ratio (38.8x).
Share Price vs Fair Value
What is the Fair Price of GNS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GNS (£26.34) is trading above our estimate of fair value (£24.79)
Significantly Below Fair Value: GNS is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Genus forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNS's forecast earnings growth (18.6% per year) is above the savings rate (0.9%).
Earnings vs Market: GNS's earnings (18.6% per year) are forecast to grow faster than the UK market (9.9% per year).
High Growth Earnings: GNS's earnings are forecast to grow, but not significantly.
Revenue vs Market: GNS's revenue (7.2% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: GNS's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GNS's Return on Equity is forecast to be low in 3 years time (11%).
Discover growth companies
How has Genus performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNS has a large one-off loss of £17.6M impacting its December 31 2021 financial results.
Growing Profit Margin: GNS's current net profit margins (6.5%) are lower than last year (7.4%).
Past Earnings Growth Analysis
Earnings Trend: GNS's earnings have declined by 1.2% per year over the past 5 years.
Accelerating Growth: GNS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GNS had negative earnings growth (-11.5%) over the past year, making it difficult to compare to the Biotechs industry average (-14.2%).
Return on Equity
High ROE: GNS's Return on Equity (7.2%) is considered low.
Discover strong past performing companies
How is Genus's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GNS's short term assets (£249.3M) exceed its short term liabilities (£140.7M).
Long Term Liabilities: GNS's short term assets (£249.3M) exceed its long term liabilities (£249.1M).
Debt to Equity History and Analysis
Debt Level: GNS's net debt to equity ratio (22.8%) is considered satisfactory.
Reducing Debt: GNS's debt to equity ratio has reduced from 36% to 31.9% over the past 5 years.
Debt Coverage: GNS's debt is well covered by operating cash flow (26.7%).
Interest Coverage: GNS's interest payments on its debt are well covered by EBIT (11.2x coverage).
Discover healthy companies
What is Genus's current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GNS's dividend (1.14%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.86%).
High Dividend: GNS's dividend (1.14%) is low compared to the top 25% of dividend payers in the UK market (5.13%).
Stability and Growth of Payments
Stable Dividend: GNS's dividend payments have been volatile in the past 10 years.
Growing Dividend: GNS's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (56.5%), GNS's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: GNS is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Wilson (62 yo)
Mr. Stephen Wilson serves as Independent Non-Executive Director of Renishaw plc since June 01, 2022. He has extensive business leadership experience, including strategic, financial and business development...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD3.49M) is above average for companies of similar size in the UK market ($USD1.91M).
Compensation vs Earnings: Stephen's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: GNS's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: GNS's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genus plc's employee growth, exchange listings and data sources
- Name: Genus plc
- Ticker: GNS
- Exchange: LSE
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£1.818b
- Shares outstanding: 65.17m
- Website: https://www.genusplc.com
Number of Employees
- Genus plc
- Matrix House
- Basing View
- RG21 4DZ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.